JP2025016545A5 - - Google Patents
Info
- Publication number
- JP2025016545A5 JP2025016545A5 JP2024186222A JP2024186222A JP2025016545A5 JP 2025016545 A5 JP2025016545 A5 JP 2025016545A5 JP 2024186222 A JP2024186222 A JP 2024186222A JP 2024186222 A JP2024186222 A JP 2024186222A JP 2025016545 A5 JP2025016545 A5 JP 2025016545A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- linker
- payload conjugate
- payload
- heavy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19163810.5 | 2019-03-19 | ||
| EP19163810 | 2019-03-19 | ||
| PCT/EP2020/057697 WO2020188061A1 (en) | 2019-03-19 | 2020-03-19 | Transglutaminase conjugation method with a glycine based linker |
| JP2022504337A JP7629902B2 (ja) | 2019-03-19 | 2020-03-19 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504337A Division JP7629902B2 (ja) | 2019-03-19 | 2020-03-19 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025016545A JP2025016545A (ja) | 2025-02-04 |
| JP2025016545A5 true JP2025016545A5 (https=) | 2025-10-21 |
Family
ID=65903991
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504337A Active JP7629902B2 (ja) | 2019-03-19 | 2020-03-19 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
| JP2024186222A Pending JP2025016545A (ja) | 2019-03-19 | 2024-10-22 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504337A Active JP7629902B2 (ja) | 2019-03-19 | 2020-03-19 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220133904A1 (https=) |
| EP (1) | EP3941526A1 (https=) |
| JP (2) | JP7629902B2 (https=) |
| KR (1) | KR20220144753A (https=) |
| CN (1) | CN113613679A (https=) |
| AU (1) | AU2020243056A1 (https=) |
| CA (1) | CA3128571A1 (https=) |
| WO (1) | WO2020188061A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019057772A1 (en) | 2017-09-19 | 2019-03-28 | Paul Scherrer Institut | METHOD FOR CONJUGATING TRANSGLUTAMINASE AND BINDING SEQUENCE |
| US11744876B2 (en) * | 2019-06-10 | 2023-09-05 | Sutro Biopharma, Inc. | Immunomodulator antibody drug conjugates and uses thereof |
| AU2021213421B2 (en) | 2020-01-31 | 2025-02-06 | Innate Pharma | Treatment of cancer |
| US20230095053A1 (en) * | 2020-03-03 | 2023-03-30 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
| KR20230069211A (ko) * | 2020-09-18 | 2023-05-18 | 아라리스 바이오테크 아게 | 아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법 |
| CN116801910A (zh) * | 2020-10-25 | 2023-09-22 | 阿拉里斯生物技术股份公司 | 生产抗体-接头偶联物的手段和方法 |
| CA3196218A1 (en) * | 2020-10-25 | 2022-04-28 | Philipp SPYCHER | Means and methods for producing antibody-linker conjugates |
| CA3196198A1 (en) | 2020-11-25 | 2022-06-02 | Manel KRAIEM | Treatment of cancer |
| CA3199925A1 (en) * | 2020-11-30 | 2022-06-02 | Menotti Ruvo | Multi-specific human albumin nanoparticles decorated with antibody fragments and loaded with cytotoxics |
| US20230181754A1 (en) | 2021-07-09 | 2023-06-15 | Bright Peak Therapeutics Ag | Modified checkpoint inhibitors and uses thereof |
| WO2023281479A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Checkpoint inhibitors conjugated to il-2, and uses thereof |
| US20230201365A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Modified cd20 antibodies and uses thereof |
| WO2023281485A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| US20230201364A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Antibody conjugates and manufacture thereof |
| AU2023223557A1 (en) * | 2022-02-22 | 2024-10-03 | Adc Therapeutics Sa | Conjugation method involving a transglutaminase at the fc region comprising a trimmed n-glycan |
| KR20240150807A (ko) | 2022-02-22 | 2024-10-16 | 아라리스 바이오테크 아게 | 2개 이상의 페이로드를 포함하는 펩티드 링커 |
| JP2025508823A (ja) | 2022-02-23 | 2025-04-10 | ブライト ピーク セラピューティクス エージー | 免疫抗原特異的ｉｌ－１８免疫サイトカイン及びその使用 |
| AR128745A1 (es) | 2022-03-09 | 2024-06-12 | Merck Patent Gmbh | Anticuerpos y conjugados anti-ceacam5 y usos de los mismos |
| CA3245954A1 (en) | 2022-05-25 | 2023-11-30 | Innate Pharma | NECTIN-4 LIAISON OFFICERS |
| EP4568997A1 (en) | 2022-08-08 | 2025-06-18 | ATB Therapeutics | Humanized antibodies against cd79b |
| CN115814111B (zh) * | 2022-12-05 | 2025-03-28 | 复旦大学附属中山医院 | 一种近红外荧光adc免疫制剂及其制备方法与应用 |
| US20240424127A1 (en) | 2023-01-11 | 2024-12-26 | Bright Peak Therapeutics Ag | Il-7 polypeptides, immunocytokines comprising same, and uses thereof |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| CN116077676B (zh) * | 2023-02-03 | 2025-09-12 | 南京大学 | 蛋白质靶向降解嵌合体及其制备方法和应用 |
| WO2025041102A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Targeted immune activation with il-18 immunocytokines |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2025082990A1 (en) | 2023-10-15 | 2025-04-24 | Araris Biotech Ag | Antibody-drug conjugates using two different types of topoisomerase i inhibitors |
| WO2025192692A1 (ja) * | 2024-03-14 | 2025-09-18 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| WO2026008881A1 (en) | 2024-07-05 | 2026-01-08 | Synaffix B.V. | Extracellular vesicles comprising biomolecule-conjugates |
| WO2026013234A1 (en) | 2024-07-10 | 2026-01-15 | Araris Biotech Ag | Triple-payload antibody-drug conjugates (adcs) |
| WO2026069134A1 (en) | 2024-09-26 | 2026-04-02 | Bright Peak Therapeutics Ag | Human therapy with il-18 immunocytokines |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6660510B2 (en) | 2001-12-17 | 2003-12-09 | Food Industry Research And Development | Transglutaminase gene of Streptoverticillium ladakanum and the transglutaminase encoded therefrom |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| AU2008215422B2 (en) | 2007-02-15 | 2011-07-14 | Ajinomoto Co., Inc. | Transglutaminase having disulfide bond introduced therein |
| KR20090123857A (ko) | 2007-02-22 | 2009-12-02 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 특이성이 개선된 트랜스글루타미나아제 변이체 |
| US9676871B2 (en) | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| US9764038B2 (en) | 2011-12-23 | 2017-09-19 | Innate Pharma | Enzymatic conjugation of antibodies |
| EP2777714A1 (en) * | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| EP3027224B1 (en) | 2013-07-31 | 2020-06-03 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates using transglutaminase |
| SI3134127T1 (sl) * | 2014-04-25 | 2020-06-30 | Rinat Neuroscience Corp. | Konjugati zdravil s protitelesi z visoko stopnjo zdravila |
| KR102451080B1 (ko) * | 2014-06-12 | 2022-10-06 | 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. | 효소적 방법을 통한 균일한 항체 약물 접합체 |
| ES2871624T3 (es) | 2014-12-19 | 2021-10-29 | Hoffmann La Roche | Transglutaminasas microbianas, sustratos para las mismas y procedimientos para el uso de las mismas |
| CA2971246C (en) | 2014-12-19 | 2020-07-14 | F. Hoffmann-La Roche Ag | Identification of transglutaminase substrates and uses therefor |
| WO2016128410A1 (en) * | 2015-02-09 | 2016-08-18 | Nbe Therapeutics Ag | Maytansine-drug conjugates of her- 2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation |
| CN107406496A (zh) | 2015-03-10 | 2017-11-28 | 百时美施贵宝公司 | 可通过转谷氨酰胺酶缀合的抗体和由其制备的缀合物 |
| CA2994741A1 (en) | 2015-08-07 | 2017-02-16 | Merck Patent Gmbh | A transglutamine tag for efficient site-specific bioconjugation |
| EP3665193A1 (en) * | 2017-08-07 | 2020-06-17 | NBE Therapeutics AG | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
-
2020
- 2020-03-19 JP JP2022504337A patent/JP7629902B2/ja active Active
- 2020-03-19 KR KR1020217033833A patent/KR20220144753A/ko active Pending
- 2020-03-19 CA CA3128571A patent/CA3128571A1/en active Pending
- 2020-03-19 CN CN202080022652.9A patent/CN113613679A/zh active Pending
- 2020-03-19 EP EP20711197.2A patent/EP3941526A1/en active Pending
- 2020-03-19 WO PCT/EP2020/057697 patent/WO2020188061A1/en not_active Ceased
- 2020-03-19 AU AU2020243056A patent/AU2020243056A1/en active Pending
- 2020-03-19 US US17/435,356 patent/US20220133904A1/en active Pending
-
2024
- 2024-10-22 JP JP2024186222A patent/JP2025016545A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025016545A5 (https=) | ||
| JPWO2020188061A5 (https=) | ||
| US20200289661A1 (en) | Cd48 antibodies and conjugates thereof | |
| JP7239558B2 (ja) | テトラマレイミドリンカー及びその使用 | |
| JP7815223B2 (ja) | 可溶性タグを有する分子および関連方法 | |
| JP2020534030A5 (https=) | ||
| EP3695852A1 (en) | Anti-mesothelin antibody and antibody-drug conjugate thereof | |
| PL172837B1 (pl) | Preparat farmaceutyczny zawierajacy koniugaty tioeterowe PL PL PL PL PL | |
| CN110240654A (zh) | 结合cd73的抗体-药物偶联物 | |
| JP2018523471A5 (https=) | ||
| JP2020510656A5 (https=) | ||
| US20190298846A1 (en) | Cell targeting conjugates | |
| JP2023522392A (ja) | 抗ｃｅａｃａｍ５抗体コンジュゲートおよびフォルフィリを含有する抗腫瘍組み合わせ | |
| JP2023529640A (ja) | 治療用コンジュゲート | |
| JP2023522396A (ja) | 抗ｃｅａｃａｍ５抗体コンジュゲート、トリフルリジン、およびチピラシルを含有する抗腫瘍組み合わせ | |
| JP2023522393A (ja) | 抗ｃｅａｃａｍ５抗体コンジュゲートおよびセツキシマブを含有する抗腫瘍組み合わせ | |
| EP3684412A1 (en) | Methods of preventing methionine oxidation in immunoconjugates | |
| JPWO2022084560A5 (https=) | ||
| NZ779213B2 (en) | Transglutaminase conjugation method with a glycine based linker | |
| NZ779213A (en) | Transglutaminase conjugation method with a glycine based linker | |
| JPWO2023072934A5 (https=) | ||
| JPWO2022058594A5 (https=) | ||
| CN101277716A (zh) | 治疗癌症的抗体 | |
| JPWO2023079057A5 (https=) | ||
| WO2025003392A1 (en) | Bioconjugation systems and uses thereof |